DBV Technologies to Attend Upcoming Investor Conferences
(Thomson Reuters ONE) -
Press Release
Montrouge, France, September 1, 2016
DBV Technologies to Attend Upcoming Investor Conferences
DBV Technologies, (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market:
DBVT), a clinical-stage specialty biopharmaceutical company, today announced
that members of its management team will present and host investor meetings at
the following investor events in September, 2016:
* Charles Ruban, Chief Commercial Officer, and Susanna Mesa, Senior Vice
President, Strategy, will host investor meetings during Citi's 11(th) Annual
Biotech Conference in Boston, MA on Thursday, September 8, 2016.
* Pierre-Henri Benhamou, Chairman & Chief Executive Officer, David Schilansky,
Chief Operating Officer and Susanna Mesa, Senior Vice President, Strategy,
will present at the Morgan Stanley Global Healthcare Conference in New York,
NY on Monday, September 12, 2016, at 2:15 pm ET.
* Susanna Mesa, Senior Vice President, Strategy, will present at the Rodman &
Renshaw 18th Annual Global Investment Conference in New York, NY on Tuesday,
September 13, 2016, at 11:40 am ET.
* Pierre-Henri Benhamou, Chairman & Chief Executive Officer and David
Schilansky, Chief Operating Officer will present at the Bank of America
Merrill Lynch Global Healthcare Conference 2016 in London, UK on Friday,
September 16, 2016, at 1:45 pm BST.
A live webcast of the Morgan Stanley Conference will be available on the
Investor Relations section of the Company's website: http://www.dbv-
technologies.com/en/investor-relations. A replay of the presentation will also
be available on DBV's website within 48 hours after the event.
About DBV Technologies
DBV Technologies developed Viaskin®, a proprietary technology platform with
broad potential applications in immunotherapy. Viaskin is based on epicutaneous
immunotherapy, or EPIT®, DBV's method of delivering biologically active
compounds to the immune system through intact skin. With this new class of self-
administered and non-invasive product candidates, the company is dedicated to
safely transforming the care of food allergic patients, for whom there are no
approved treatments. DBV's food allergies programs include ongoing clinical
trials of Viaskin Peanut and Viaskin Milk, and preclinical development of
Viaskin Egg. DBV isalso pursuing a human proof concept clinical study of Viaskin
Milk for the treatment of Eosinophilic Esophagitis, and exploring potential
applications of its platform in vaccines and other immune diseases.
DBV Technologies has global headquarters in Montrouge, France and New York, NY.
Company shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN
code: FR0010417345), part of the SBF120 index, and traded on the Nasdaq Global
Select Market in the form of American Depositary Shares (each representing one-
half of one ordinary share) (Ticker: DBVT). For more information on DBV
Technologies, please visit our website: www.dbv-technologies.com
DBV Technologies Contact
Susanna Mesa
Senior Vice President, Strategy
+1 212-271-0861
susanna.mesa(at)dbv-technologies.com
Media Contacts
Erinn White, Centron PR
+1 646-722-8822
ewhite(at)centronpr.com
Media Contacts, Europe
Caroline Carmagnol, Alize RP - Relation Presse
+33 (0)6 64 18 99 59
caroline(at)alizerp.com
PDF Version:
http://hugin.info/156437/R/2038534/759741.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: DBV Technologies via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 01.09.2016 - 07:30 Uhr
Sprache: Deutsch
News-ID 492134
Anzahl Zeichen: 4387
contact information:
Town:
Bagneux
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 241 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DBV Technologies to Attend Upcoming Investor Conferences"
steht unter der journalistisch-redaktionellen Verantwortung von
DBV Technologies (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
